Floatz logo

Telaglenastat

Stage IV Lung Cancer AJCC v8

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
81/ 100

Competitive context

303 Active assets in the Stage IV Lung Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
Carboplatin
SystImmune Inc.
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
University of Vermont
Phase 4BB
PROPOFOL
Kaohsiung Medical University Chung-Ho Memorial Hospital
Phase 4BB
ETOPOSIDE
SystImmune Inc.
Phase 3BB
Nivolumab
University of Chicago
Phase 4BB

View all 50 →

Same molecule, other indications

Telaglenastat is also rated in:

Metastatic Lung Non-Small Cell CarcinomaDormant
BB
Indicative ·
65 / 100
View asset →
renal cell carcinomaDormant
B
Indicative ·
62 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →